REFERENCES
- Bedikian A Y. Metastatic uveal melanoma therapy: Current options. Int Ophthalmol Clin 2006; 46: 151–166
- Mudhar H S, Parsons M A, Sisley K, Rundle P, Singh A, Rennie I G. A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathology 2004; 45: 1–12
- Kivela T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin 2006; 46: 133–149
- Soengas M S, Lowe S W. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22: 3138–3151
- Vermeulen K, Van Bockstaele D R, Berneman Z N. Apoptosis: Mechanisms and relevance in cancer. Ann Hematol 2005; 84: 627–639
- Salvesen G S, Duckett C S. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401–410
- Miller L K. Baculovirus interaction with host apoptotic pathways. J Cell Physiol 1997; 173: 178–182
- Nachmias B, Ashhab Y, Bucholtz V, et al. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: Implications for drug-resistant melanoma. Cancer Res 2003; 63: 6340–6349
- Vucic D, Stennicke H R, Pisabarro M T, Salvesen G S, Dixit V M. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000; 10: 1359–1366
- LaCasse E C, Baird S, Korneluk R G, MacKenzie A E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247–3259
- Grossman D, Altieri D C. Drug resistance in melanoma: Mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001; 20: 3–11
- Ben Simon G J, Abulafia A, Pe'er J. Apoptosis inhibitor, survivin, in posterior uveal melanoma: Comparison among primary tumors, tumors resistant to brachytherapy, tumors with liver metastases, and liver metastases. Curr Eye Res 2006; 31: 3251–3257
- Li H, Niederkorn J Y, Neelam S, Alizadeh H. Resistance and susceptibility of human uveal melanoma cells to TRAIL-induced apoptosis. Arch Ophthalmol 2005; 123: 654–661
- Folberg R, Leach L, Valyi-Nagy K, et al. Modeling the behavior of uveal melanoma in the liver. Invest Ophthalmol Vis Sci 2007; 48: 2967–2974
- Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993; 100: 1389–1398
- Pe'er J, Stefani F H, Seregard S, et al. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study. Br J Ophthalmol 2001; 85: 1208–1212
- Tschentscher F, Prescher G, Zeschnigk M, Horsthemke B, Lohmann D R. Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet 2000; 122: 7–13
- Worley L A, Onken M D, Person E, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res 2007; 13: 1466–1471
- Meir T, Dror R, Yu X, et al. Molecular characteristics of liver metastases from uveal melanoma. Invest Ophthalmol Vis Sci 2007; 48: 90–96
- Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): An emerging therapeutic target in cancer. Semin Cancer Biol 2004; 14: 231–243
- Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 2004; 23: 39–48
- Hussein M R, Haemel A K, Wood G S. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003; 199: 275–288
- Li H, Niederkorn J Y, Neelam S, Alizadeh H. Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment. Exp Eye Res 2006; 83: 176–182